SHH and medulloblastoma: Although subgroup stability at relapse supports the use of diagnostic biopsy to define subgroup-directed therapies at relapse (e.g., SHH pathway inhibitors) (Rudin et al., 2009), we now understand that medulloblastomas display unique and emergent biology at relapse, which cannot be predicted at diagnosis.